| Dermatitis, Atopic
Opzelura vs Zoryve Cream
Side-by-side clinical, coverage, and cost comparison for dermatitis, atopic.Deep comparison between: Opzelura vs Zoryve with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsZoryve has a higher rate of injection site reactions vs Opzelura based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Zoryve but not Opzelura, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Opzelura
Zoryve
At A Glance
Topical
Twice daily
JAK inhibitor
Topical
Daily
PDE4 inhibitor
Indications
- Dermatitis, Atopic
- Vitiligo
- Psoriasis vulgaris
- Dermatitis, Atopic
Dosing
Dermatitis, Atopic Apply a thin layer topically twice daily to affected areas of up to 20% body surface area; do not use with occlusive dressings; adults and pediatric patients 12 years and older: max one 60 gram tube per week or one 100 gram tube per 2 weeks; pediatric patients 2 to 11 years: max one 60 gram tube per 2 weeks.
Vitiligo Apply a thin layer topically twice daily to affected areas of up to 10% body surface area; max one 60 gram tube per week or one 100 gram tube per 2 weeks.
Psoriasis vulgaris Apply ZORYVE cream, 0.3%, to affected areas once daily in adult and pediatric patients 6 years of age and older.
Dermatitis, Atopic Apply ZORYVE cream, 0.15%, once daily for patients 6 years of age and older; apply ZORYVE cream, 0.05%, once daily for pediatric patients 2 to 5 years of age.
Contraindications
—
- Moderate to severe liver impairment (Child-Pugh B or C)
Adverse Reactions
Most common (>=1%) - Atopic Dermatitis nasopharyngitis, diarrhea, bronchitis, ear infection, eosinophil count increased, urticaria, folliculitis, tonsillitis, rhinorrhea, upper respiratory tract infection, COVID-19, application site reactions, pyrexia, white blood cell decreased
Most common (>=1%) - Nonsegmental Vitiligo application site acne, application site pruritus, nasopharyngitis, headache, urinary tract infection, application site erythema, pyrexia
Most common (>=1%), Plaque Psoriasis Diarrhea, headache, insomnia, nausea, application site pain, upper respiratory tract infection, urinary tract infection
Most common (>=1%), Atopic Dermatitis Headache, nausea, application site pain, diarrhea, vomiting, upper respiratory tract infection, rhinitis, conjunctivitis
Pharmacology
Ruxolitinib is a JAK inhibitor that inhibits JAK1 and JAK2, which mediate signaling of cytokines and growth factors important for hematopoiesis and immune function; JAK signaling involves STAT recruitment to cytokine receptors, activation, and nuclear localization leading to modulation of gene expression.
PDE4 inhibitor; roflumilast and its active metabolite (roflumilast N-oxide) inhibit PDE4, a major cyclic AMP-metabolizing enzyme, leading to accumulation of intracellular cyclic AMP.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Opzelura
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (10/12)
Zoryve
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (9/12) · Qty limit (9/12)
UnitedHealthcare
Opzelura
- Covered on 4 commercial plans
- PA (5/8) · Step Therapy (4/8) · Qty limit (5/8)
Zoryve
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (4/8) · Qty limit (4/8)
Humana
Opzelura
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
Zoryve
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAssistance Fund: Atopic Dermatitis: Waitlist
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
$0
Arcutis Cares Patient Assistance: ZoryveCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
OpzeluraView full Opzelura profile
ZoryveView full Zoryve profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.